Results

Conclusions: We report the first two cases of adrenal myelolipoma involved by plasma cell myeloma, a rare and subtle finding that has significant clinical implications.
Myelolipoma, considered a benign neoplasm, exhibits a distinctive and intriguing morphology. It is composed of mature adipose tissue with mixed hematopoietic precursors that mimic normal bone marrow histology. While the most common site is the adrenal gland, extra-adrenal myelolipomas account for about 15% of cases, 1 with sites varying from the presacral region, 2 mediastinum, 3 perirenal regions, 4 nasal cavity, 5 and spleen. 6 Most myelolipomas are incidentally identified during workup for other diseases or during autopsies. At autopsy, the incidence is around 0.08% to 0.4%. 7 In addition, myelolipomas are usually diagnosed by imaging, and the management is commonly observation only. Surgical excision is considered only for symptomatic patients or large masses. 8, 9 Hematologic neoplasms arising in myelolipomas are rare, with only a few case reports describing this phenomenon, [10] [11] [12] [13] [14] and none of these are plasma cell neoplasms. To our knowledge, we report the first two cases of adrenal myelolipoma involved by a plasma cell myeloma and the presence and frequency of hematologic neoplasms within myelolipomas at our institution. We also performed a comprehensive literature review of coexisting adrenal myelolipoma and hematologic neoplasms.
Materials and Methods
Retrospective Case Review and Demographic Data Collection
The Stanford institutional review board approved this study. Myelolipoma cases were retrieved from the Stanford pathology archive from 1999 to 2016 after encountering the index case (described in detail in the Results section). All of the available slides were reviewed to confirm the diagnosis. Clinicopathologic data, including age, sex, site, laterality, preoperative diagnosis, medical history, and laboratory data, were gathered when available.
Immunohistochemical Stains and RNA In Situ Hybridization
Immunohistochemical stains and RNA in situ hybridization studies were performed to characterize the plasma cell population on selected formalin-fixed, paraffin-embedded tissue blocks. The immunohistochemical studies included stains for CD138 (B-A38, 1:25; Cell Marque, Rocklin, CA), CD3 (polyclonal, 1:100; Cell Marque), and CD20 (L26, 1:1,000; Dako, Carpinteria, CA). Antigen retrieval was achieved using the Ventana alkaline retrieval solution (CC1) for CD3 and CD138 (Ventana Medical Systems, Tucson, AZ) and the Leica alkaline antigen retrieval solution (ER2) for CD20 (Leica, Buffalo Grove, IL). Immunostaining for CD138 and CD3 was performed using the Ventana XT platform autostainer (Ventana Medical Systems), and immunostaining for CD20 was performed using the Leica Bond Max autostainer. We performed κ and λ light chain RNA in situ hybridization using predilution techniques on the Ventana XT platform autostainer and Ventana ISH I'view detection system (Ventana Medical Systems) with protease pretreatment. A cocktail of four probes for both κ light chain (cat. 760:1201-1204; Ventana Medical Systems) and λ light chain (cat. 760:1205-1208; Ventana Medical Systems) was used.
Results
Index Case (Case 1)
An 81-year-old man with a medical history of chronic hypertension sought treatment at an outpatient clinic with chronic low back pain. The pain did not improve after empirical nonsteroidal anti-inflammatory treatment. Magnetic resonance imaging of the spine was performed to further evaluate the nature of the back pain, and an incidental 8.3-cm right adrenal mass was identified. The plasma levels of metanephrine, normetanephrine, adrenocorticotropic hormone, renin, aldosterone, and random cortisol levels were within normal parameters. An adrenalectomy was recommended to alleviate the symptoms. The excised specimen contained a well-circumscribed mass with the residual adrenal gland ❚Image 1❚. The cut surfaces were heterogeneous, with intervening hemorrhagic and fatty areas. Microscopic examination showed mature adipose tissue with trilineage hematopoiesis ❚Image 2A❚ and ❚Image 2B❚. Focally, sheets of plasma cells were identified with dysplastic features such as binucleation, prominent nucleoli, and open chromatin ❚Image 2C❚. Immunohistochemical stains and RNA in situ hybridization were performed, and numerous CD138-postive, λ light chain-restricted plasma cells were identified ❚Image 2D❚, ❚Image 2E❚, and ❚Image 2F❚. Interestingly, the plasma cells in the areas of morphologically unremarkable, mixed hematopoiesis were also light chain restricted ❚Image 2G❚, ❚Image 2H❚, and ❚Image 2I❚. The patient's serum calcium level was normal (9.8 mg/dL) with an elevated serum creatinine (3.5 mg/dL). The complete peripheral blood count showed borderline anemia (hemoglobin, 9.6 g/dL). Imaging studies did not identify any osteolytic lesions. A bone marrow aspirate and core biopsy were performed at an outside facility, and per report, the specimen contained a hypercellular marrow (70% cellularity) with sheets of plasma cells (enumerated as 53% plasma cells). The plasma cells were λ restricted, consistent with the findings in the adrenal gland. Cytogenetic studies revealed a normal karyotype, and a skeletal survey showed no discernable lytic lesions. The urine κ free light chain measured 6.7 mg/dL and the λ free light chain measured 387.0 mg/dL. The serum κ free light chain measured 12.0 mg/L, and the λ free light chain measured 2,368.0 mg/L. Overall, the findings are consistent with symptomatic multiple myeloma: more than 10% bone marrow plasma cells plus renal insufficiency ❚Image 1❚ Gross findings of index case (case 1). Gross picture of the adrenal myelolipoma involved by plasma cell myeloma with residual adrenal gland at the periphery (bottom left).
and anemia, with an involved/uninvolved serum free light chain ratio of 100 or more. The patient has received six cycles of dexamethasone + bortezomib. The serum λ free light chain normalized after the first cycle of therapy, and the patient has been clinically stable without evidence of disease progression 1 year after the adrenalectomy.
Retrospective Review of Adrenal Myelolipomas
In light of our index case, we retrospectively reviewed all of the adrenal myelolipomas diagnosed from 1999 to 2016 in our institute. In total, 23 cases were identified, which consisted of 19 (83%) surgical cases and four (17%) autopsy cases. The average patient age was 59.4 years (range, 34-84 years), and male to female ratio was 1.88:1. The tumor size was quite variable, ranging from 0.2 cm to 33 cm, with an average of 8 cm. Ten cases were on the left side and 10 were on the right; three had unspecified laterality. For surgical resection cases, the myelolipomas were the targeted lesions in 85.2% of the cases. The preoperative clinical diagnoses included myelolipoma, adrenal adenoma, pheochromocytoma, metastasis, and liposarcoma. In the other 14.8% of the cases, the myelolipomas were incidental findings mainly secondary to a renal neoplasm.
A second case of plasma cell neoplasm within an adrenal myelolipoma was identified as a result of this retrospective review with detailed information below.
Case 2
A 71-year-old woman initially had a chief complaint of cold sweats and palpitations. During the clinical workup, an abdominal ultrasound and a computed tomography scan demonstrated a 6-cm right-sided adrenal mass. Laboratory studies provided no support for a biochemically ❚Image 2❚ (cont) G, H&E-stained image of mixed hematopoiesis in background myelolipoma (×200). κ (H) and λ (I) in situ hybridization of the mixed hematopoiesis highlighting intermixed λ-restricted plasma cells (×200). active tumor; however, an adrenalectomy was indicated because of its size. The plasma norepinephrine was slightly above the normal upper limit (561 pg/mL; reference range, 80-520 pg/mL). The patient was not anemic ( hemoglobin, 14.1 g/dL) but had longstanding mild thrombocytopenia (platelet count, 89,000/µL), which was attributed to possible autoimmune hepatitis. During the preparation for surgery, a hematology consultation was requested for thrombocytopenia. While no obvious dysplastic features were observed on the peripheral blood smear, a decision was made to perform a bone marrow biopsy to clarify the etiology of the thrombocytopenia. The bone marrow aspirate showed atypical multinucleated plasma cells, constituting 13% of the cells present. The bone marrow biopsy specimen showed hypercellular marrow (85%), with 30% to 40% CD138-positive plasma cells. Stains for κ and λ light chain in situ hybridization highlighted a κ light chainrestricted plasma cell population. The karyotype was normal (46, XX). The adrenalectomy was performed, and the specimen contained a single encapsulated mass measuring 7 × 6.5 × 4 cm. The cut surfaces were maroon with multiple tan, irregular nodules. Microscopic sections demonstrated mature adipose tissue with scattered islands of hematopoietic precursors. A large number of atypical plasma cells diffusely infiltrated the adipose tissue ❚Image 3A❚ and were highlighted by CD138 ❚Image 3B❚. RNA in situ hybridization for κ and λ light chains confirmed a κ light chain-restricted plasma cell population ❚Image 3C❚ and ❚Image 3D❚. These findings are compatible with a myelolipoma involved by a plasma cell myeloma.
❚Image 3❚ Microscopic findings of case 2. H&E stain (A), CD138 stain (B), κ (C), and λ (D) in situ hybridization of the atypical plasma cell population (×200).
Additional clinical workup was performed postoperatively. The serum calcium was 9.7 mg/dL, and the serum creatinine was 1.0 mg/dL. The serum protein immunofixation electrophoresis showed an abnormal band identified as immunoglobulin A κ (0.9 g/dL), and β 2 microglobulin was elevated at 3,441 ng/mL. A skeletal survey showed no lytic lesions. The patient initially received thalidomide and dexamethasone. Due to intolerance to thalidomide, the therapy was switched to melphalan and prednisone. Six months after the initial diagnosis, her clinical course was complicated by recurrent pericardial effusions that were involved by the plasma cell myeloma. Additional therapies included bortezomib, cyclophosphamide, and a pericardial window. Three years after the initial diagnosis, the patient was admitted for pancytopenia and altered mental status after falls and subsequently died. An autopsy was performed, demonstrating extensive involvement by the plasma cell myeloma in the vertebral body, rib, right kidney, and spleen.
In addition to the two cases described above, additional immunohistochemical or flow cytometric studies for possible hematologic neoplasms were performed on three cases at the time of diagnosis due to clinical suspicion. One case contained a λ-restricted monoclonal B-cell population, expressing CD19, CD20, and CD22 and lacking CD5, CD10, FMC7, and CD23 by flow cytometry (performed on a prior fine-needle aspiration of the myelolipoma). Fluorescence in situ hybridization for BCL2 was negative. Molecular studies were performed and a MYD88 mutation (p.L265P (c.794T>C)) was noted in the peripheral blood. The patient was referred to a hematologist, and it was determined that this was best characterized as a monoclonal B-cell lymphocytosis. The bone marrow was not examined in this patient. The second case demonstrated atypical lymphoid aggregates composed of small, mature lymphocytes with clumped chromatin. Immunohistochemical stains showed predominantly CD20-positive B cells without coexpression of CD5 or CD10. The BCL1 stain was negative, arguing against a diagnosis of mantle cell lymphoma. B-cell clonality testing was negative; hence, overall, it was favored to be a reactive process. The third case showed small clusters of binucleate plasma cells at the periphery of fat necrosis ❚Image 4A❚. RNA in situ stains for κ and λ light chains demonstrated polytypic plasma cells ❚Image 4B❚ and ❚Image 4C❚. We did not identify any patients with unexplained bone marrow suppression, anemia, thrombocytopenia, or pancytopenia. In summary, no other types of hematologic neoplasms were identified in the retrospective review of adrenal myelolipomas.
All myelolipomas on histologic sections showed variable densities of hematopoietic elements. The two cases with plasma cell myelomas consistently showed aggregates of atypical plasma cells that were large enough to fill a single ×10 field. Immunohistochemical stains for CD138 and κ and λ light chain in situ hybridization were performed in all 23 cases. The two cases with plasma cell myeloma demonstrated monotypic plasma cells: one that was λ restricted and one that was κ restricted. The remaining 21 cases demonstrated plasma cells with mixed polytypic light chain expression. Interestingly, the percentages of polytypic plasma cells in cases without plasma cell myeloma were universally low, comprising less than 1% of the total cellularity based on CD138 immunohistochemical stains.
Literature Review of Myelolipomas Involved by Hematologic Neoplasia
Rare cases of hematologic neoplasms coexisting with other adrenal neoplasms, such as cortical adenoma, pheochromocytoma, or adrenal cortical carcinoma, have also been reported. [15] [16] [17] Due to the presence of hematopoiesis in myelolipomas, it is reasonable to postulate that hematologic neoplasms have the potential to arise within a myelolipoma, although most cases likely represent involvement of the bone marrow-like niche within the myelolipoma by a systemic hematopoietic neoplasm. Demonstration that such a tumor actually arose in the myelolipoma would require confirmation that it was the only site of disease, but the distinction is unlikely to be significance clinically outside of staging considerations. These case reports include three cases of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), 10, 12, 18 one case of splenic marginal zone lymphoma, 19 one case of an unspecified low-grade B-cell neoplasm, 14 one case of classical Hodgkin lymphoma, 13 and one case of acute myeloid leukemia. 11 A summary of the literature review is provided in ❚Table 1❚.
Discussion
Myelolipomas in their pure form are regarded as benign neoplasms composed of mature adipose tissue and normal hematopoiesis with a predilection for the adrenal gland. Prior studies show that myelolipomas are most commonly seen in the fifth to seventh decade of life, with a roughly equal male to female ratio. 20 It is classically an incidental radiographic finding requiring only conservative management unless they are large, symptomatic, or associated with an endocrine disorder. 8 To date, most of the literature involving myelolipomas has evaluated the diagnostic features by imaging as well as the clinical and demographic features and management. 1, 8, 21 There have been very few reports of myelolipoma with an associated secondary neoplasm, hematologic or nonhematologic, and these reports chiefly consist of single case reports or small case series (Table 1) . These associated neoplasms consist of adrenal cortical adenoma/carcinoma, pheochromocytoma, ovarian steroid cell tumor, CLL/SLL, splenic marginal zone lymphoma, acute myelogenous leukemia, low grade B-cell lymphoma, and classical Hodgkin lymphoma. [10] [11] [12] [13] [14] [15] [16] [17] [18] 22 After a thorough review of the literature, it is clear that secondary neoplasia in association with myelolipomas is an uncommon and possibly underreported phenomenon.
Here we report the first two cases of adrenal myelolipoma involved by plasma cell myeloma. Our study is also the largest retrospective series that includes an unbiased systematic review to determine the frequency of secondary neoplasia with an emphasis on the evaluation for secondary plasma cell neoplasia. These tumors consistently show an increased concentration of plasma cells with nuclear atypia visible at ×100 magnification (with ×10 ocular and ×10 objective), and their clonal nature is confirmed via ancillary studies. The incidence of plasma cell neoplasia in adrenal myelolipomas at our institution is 9% (2/23); although only a small number of cases were analyzed, this is a sizable cohort for a rare tumor. From our experience, in contrast to epithelial neoplasms, hematologic neoplasia is morphologically subtle in a background of hematopoiesis, and thus the use of appropriate ancillary studies may aid in recognition of abnormal hematologic proliferations.
In the two plasma cell myeloma cases, although the myelolipoma was first identified before any signs of hematolymphoid malignancy, both patients had bone marrow involvement. It is difficult, if not impossible, to ❚Image 4❚ Microscopic findings of myelolipoma with reactive plasma cells. H&E stain (A), κ (B), and λ (C) in situ hybridization (×200). determine the spatiotemporal relationship. As a bone marrow-like niche exists in myelolipomas, neoplastic plasma cells in these cases are likely responding to the same signals that other hematopoietic precursors respond to in the establishment of this niche, and we expect that in most cases myelolipoma involvement reflects systemic bone marrow involvement by the same process. Due to the presence of hematopoietic elements in myelolipomas, it is reasonable to postulate that hematolymphoid neoplasms have the potential to arise from myelolipomas, but this would require excluding other sites of disease. The current cases would not be considered extramedullary plasmacytomas, as the plasma cells are not forming a mass but involving the marrow-like space diffusely. As this situation is very uncommon and it is not clear how closely the myelolipoma involvement approximates general bone marrow involvement, regular staging with bone marrow biopsy would be required in any case. The other less probable mechanism is that the presence of plasma cell myeloma triggered the myelolipoma. As myelolipoma-like changes may occur in other lesions, the pathogenesis of these lesions (and even whether they are neoplastic) remains obscure. If the prevalence of hematopoietic neoplasms is higher in myelolipomas than in the overall population (which cannot currently be established given the small number of known cases), this would support the notion that such neoplasms may somehow encourage the formation of myelolipomas. There is no association we are aware of that myelolipomas are associated with extramedullary hematopoiesis in other sites, so it seems unlikely that marrow-occupying lesions associated with extramedullary hematopoiesis generally lead to myelolipoma formation as just another site of extramedullary hematopoiesis. Except for the two plasma cell myeloma cases, the other 21 patients in our study showed no evidence of bone marrow failure or a mass-occupying process (such as metastatic carcinoma) that could drive extramedullary hematopoiesis. Further functional studies, such as animal models and neoplastic cell clonal analysis, would be required to elucidate the precise pathogenesis of hematolymphoid malignancies in myelolipomas.
Morphologically, the differential diagnosis of myelolipoma in adrenal glands includes adrenal cortical adenoma with myelolipomatous metaplasia, lipoma, angiolipoma, liposarcoma, and teratoma. [23] [24] [25] [26] A pure hematopoietic proliferation admixed with mature adipose tissue resulting in a mass lesion is pathognomonic for the diagnosis of myelolipoma. Similar to other sites of extramedullary hematopoiesis, usually no discernable reticular sinusoids or bone spicules are noted in myelolipomas, with the rare exception of heterotopic bone formation. 27 Adrenal cortical adenoma with myelolipomatous metaplasia can be distinguished from myelolipoma by the predominance of adrenal cortical proliferation. Lipomas, including their variants, should lack hematopoietic elements. The lack of cytologic atypia or nonmesodermal elements will aid in the distinction from sarcoma and teratoma, respectively.
In summary, we have reviewed the coexistence of hematologic neoplasms in myelolipomas in our institution, with plasma cell neoplasia (specifically, plasma cell myeloma) being the only type of coexisting hematologic neoplasm in this series. A literature review shows rare case reports of various types of lymphoma or leukemia but none of plasma cell myeloma. It is important for diagnosticians ❚Table 1❚ Summary of Myelolipomas With Associated Hematologic Neoplasms
